| Dr Andrea Senteney Fiscus, PHD | |
|
1643 24th St W, Suite 309, Billings, MT 59102-2677 | |
| (406) 671-0454 | |
| Not Available |
| Full Name | Dr Andrea Senteney Fiscus |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 27 Years |
| Location | 1643 24th St W, Billings, Montana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356343842 | NPI | - | NPPES |
| 490603 | Medicaid | MT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TC0700X | Psychologist - Clinical | 319 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrea Senteney Fiscus, PHD Po Box 20976, Billings, MT 59104-0976 Ph: (406) 671-0454 | Dr Andrea Senteney Fiscus, PHD 1643 24th St W, Suite 309, Billings, MT 59102-2677 Ph: (406) 671-0454 |
News Archive
BerGenBio AS today announced the start of a Phase 1 Clinical Trial for BGB324, a first-in-class small molecule inhibitor of AXL tyrosine kinase. BGB324 is a highly selective, oral AXL inhibitor that blocks the epithelial-mesenchymal transition (EMT), which is a key driver of metastasis (cancer spread) and drug-resistance. The Phase 1 clinical trial of BGB324 is a single ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BGB324.
An experimental drug that works by blocking the export of key control molecules from the nucleus of cancer cells shows promise as a treatment for chronic lymphocytic leukemia (CLL) and other incurable B-cell malignancies, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.
The American Board of Addiction Medicine Foundation today accredited 10 training programs, the nation's first post-graduate addiction medicine residencies for physicians. The Foundation also released its Program Requirements and Curriculum Objectives, national guidelines for addiction medicine residencies.
› Verified 3 days ago
Dr. Lindell Lewis Gumper, JD, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 303 North Broadway, Suite 822, Billings, MT 59101 Phone: 406-446-4422 | |
Robert E. Tompkins, EDD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1018 N 30th St, Billings, MT 59101 Phone: 406-259-2487 | |
John C. Andre, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1020 N 27th St, Billings, MT 59101 Phone: 406-238-2500 | |
Dr. Alan John Bauer, ED.D. Psychologist Medicare: Accepting Medicare Assignments Practice Location: 1925 Grand Ave, Suite 125, Billings, MT 59102 Phone: 406-248-3558 | |
Daniel Wiegert, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1643 24th St W Ste 103, Billings, MT 59102 Phone: 406-662-8802 | |
William Bredehoft, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1020 N 27th St, Billings, MT 59101 Phone: 406-238-2500 | |
Juliet F Lamonaca, PSY.D. Psychologist Medicare: Medicare Enrolled Practice Location: 1629 Avenue D Ste C8, Billings, MT 59102 Phone: 406-969-6210 Fax: 844-810-1486 |